Composition of tiacumicin compounds
A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided.
1. A pharmaceutical composition comprising as the active ingredient a tiacumicin B compound, analogues thereof, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, and xanthan gum as an excipient, wherein the excipient is present in an amount to prevent foaming of the tiacumicin B compound in water.
2. The composition according to claim 1 , wherein the active ingredient is fidaxomicin.
3. The composition according to claim 1 , wherein the composition further contains microcrystalline cellulose or a sugar.
4. The composition according to claim 3 , wherein the sugar is selected from the group consisting of D-mannitol, erythritol, isomalt and trehalose.
5. The composition according to claim 1 , wherein the composition further contains one or more of a disintegrant.
6. The composition according to claim 1 , wherein the composition further contains sodium starch glycolate.
7. The composition according to claim 1 , wherein the composition further contains partially pregelatinised starch.
8. The composition according to claim 1 , wherein the composition is in the form of a dry powder for an aqueous suspension, a dry granulate for an aqueous suspension or a dispersible tablet for an aqueous suspension.
9. The composition of claim 1 , wherein the analogue of tiacumicin B is selected from the group consisting of dialkyltiacumicins and bromotiacumicins.
10. The composition of claim 1 , wherein the pharmaceutical composition is an oral pharmaceutical composition.